Autism & ADHD:
Supporting Every Child’s Potential
Understanding Autism & ADHD‍
Non-invasive Cytotron RFQMR-FRB therapy targeting neural connectivity, attentionregulation, and sensory processing in Autism Spectrum Disorder and ADHD. CDSCOapproved. Bengaluru.
‍
Autism Spectrum Disorder (ASD): ASD is characterised by differences in social communication and interaction, restricted and repetitivepatterns of behaviour, and variable sensory processing. Underlying these presentations is a pattern ofatypical neural connectivity: local over-connectivity within specific brain regions and long-range underconnectivity between regions — particularly the prefrontal cortex, temporal lobes, and the default modenetwork. Synaptic density and BDNF levels are typically reduced. GABAergic inhibition is dysregulated,contributing to sensory hypersensitivity and cortical excitability. There is no cure for ASD. The goal oftherapy is functional improvement — supporting the brain’s own capacity to build more effectiveconnections.

Attention Deficit Hyperactivity Disorder (ADHD):  ADHD is characterised by persistent inattention, hyperactivity, and impulsivity that impair functioningacross settings. The neurobiological basis is primarily a dysfunction in prefrontal-subcortical circuitsgoverning executive function — specifically deficits in dopaminergic and noradrenergic neurotransmissionthat impair working memory, sustained attention, response inhibition, and planning. Structural andfunctional imaging consistently shows reduced activation and connectivity in the prefrontal cortex and itsconnections to the basal ganglia and cerebellum during attentional tasks. ADHD is typically managed withstimulant medication and behavioural interventions; Cytotron is positioned as a complementary modality.‍
White checkmark symbol inside a gold circular background.
Improving social engagement, communication, and eye contact
White checkmark symbol inside a gold circular background.
Supporting sustained attention, focus, and impulse regulation
White checkmark symbol inside a gold circular background.
Reducing sensory hypersensitivity and emotional dysregulation
White checkmark symbol inside a gold circular background.
Complementing ABA, speech therapy, occupational therapy, and medication
Understanding
Autism and ADHD
Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Disorder (ADHD) are bothneurodevelopmental conditions rooted in differences in brain connectivity, neurotransmitter signalling, and corticalorganisation. While they are distinct diagnoses, they frequently co-occur — an estimated 30–80% of individualswith autism also meet diagnostic criteria for ADHD — and they share overlapping biophysical signatures thatRFQMR-FRB therapy can address.
PRECISION ADMISSION
BEFORE TREATMENT BEGINS
Clinical Review Assessment Table
Assessment Area What is Reviewed
Medical/Injury History Diagnosis history, prior neurological events, birth and developmental history, co-occurring conditions, current medications
Neuroimaging MRI of the brain is required for dosimetry planning. The treating team reviews existing imaging and may request updated scans before confirming treatment
Implants/Devices Any metallic implants, cochlear implants, cardiac devices, VP shunts, or other implanted hardware. Presence of an implant does not automatically exclude treatment but must be disclosed and formally assessed by the clinical team
Active Conditions Active infections, uncontrolled seizure disorders requiring acute management, recent surgical procedures, or other conditions that may affect treatment timing or safety
Current Treatment Ongoing ABA, speech, occupational, or pharmacological management — to confirm Cytotron is integrated appropriately and no conflicts exist with current protocols
How RFQMR-FRB Therapy Helps?
In both ASD and ADHD, the central neurobiological challenge is not structural destruction of neurons — as instroke or HIE — but rather suboptimal connectivity, dysregulated neurotransmission, and an atypical biophysicalenvironment that limits the brain’s ability to form and strengthen the circuits it needs. RFQMR-FRB therapy actson the underlying cellular and molecular environment to support the brain’s own capacity for reorganisation andfunctional improvement.

The therapy delivers precisely calibrated rotating electromagnetic pulses in the non-ionising spectrum. Thesepulses modulate transmembrane potential, activate endogenous neurotrophic and synaptic plasticity pathways,and support the biophysical conditions necessary for improved neural communication.
Network diagram with a central circle connected to six outer circles by lines.
BDNF Upregulation — Synaptic Density and Connectivity
Brain-Derived Neurotrophic Factor (BDNF) is a critical regulator of synaptic strength, dendritic branching,and neural circuit formation. BDNF levels are consistently found to be reduced in individuals with ASD andADHD. RFQMR stimulation upregulates BDNF expression, promoting the growth and strengthening ofsynaptic connections. In the context of autism, increased BDNF activity supports the long-rangeconnectivity deficits that underlie social and communicative processing. In ADHD, it supports thestrengthening of prefrontal circuits involved in sustained attention and working memory.
Network diagram with a central circle connected to six outer circles by lines.
Ca² -Calmodulin-CREB Pathway — Synaptic Plasticity
RFQMR promotes controlled, therapeutic calcium influx through voltage-gated channels. Intracellularcalcium activates calmodulin, which phosphorylates CREB (cAMP Response Element-Binding protein).Activated CREB drives gene transcription essential for synaptic plasticity, long-term potentiation, and theformation of new neural pathways. This pathway is fundamental to the brain’s capacity to reorganise itscircuitry in response to experience — a process that is impaired in both ASD and ADHD. CREB activationsupports the consolidation of new behavioural and cognitive patterns acquired through concurrent therapy.
Network diagram with a central circle connected to six outer circles by lines.
Transmembrane Potential (TMP) Normalisation — Cortical Regulation
Neurons in the autistic and ADHD brain exhibit atypical transmembrane potential patterns, contributing todysregulated cortical excitability — a state associated with sensory hypersensitivity, motionaldys regulation, and the reduced signal-to-noise ratio in attentional networks. RFQMR-FRB directlymodulates TMP across target neural tissue, working toward a more balanced electrochemicalenvironment. This contributes to reduced cortical hyperexcitability, improved sensory gating, and a calmerbaseline state from which behavioural and cognitive improvement can proceed.
Network diagram with a central circle connected to six outer circles by lines.
MAPK/ERK Cascade — Neural Progenitor and Glial Support
The MAPK/ERK signalling cascade, stimulated by RFQMR-induced biophysical modulation, promotes theactivity of neural progenitor cells and supports glial cell function. In neurodevelopmental contexts, glialcells — particularly astrocytes and oligodendrocytes — play critical roles in synapse formation, myelinationof developing circuits, and the metabolic support of active neurons. Supporting glial health and progenitoractivity contributes to the broader cellular environment in which improved connectivity can develop.
Network diagram with a central circle connected to six outer circles by lines.
Dopaminergic and GABAergic Circuit Support
ADHD is fundamentally a disorder of dopaminergic and noradrenergic prefrontal signalling. ASD involvesdysregulated GABAergic inhibitory tone, contributing to sensory hypersensitivity and social communicationdifficulties. RFQMR’s modulation of TMP and activation of neurotrophic factors — particularly BDNF andGDNF — supports the health and signalling efficiency of these neurotransmitter systems. GDNF,upregulated during RFQMR therapy, provides trophic support for dopaminergic neurons. ImprovedGABAergic tone, supported by TMP normalisation, contributes to calmer sensory processing and reducedcortical overactivation.
What Improvement Looks Like
Social Communication and Engagement
In children with ASD, families have reported improvements in eye contact, responsiveness to their name, turntaking in interaction, and the initiation of social contact. Verbal children may show expanded vocabulary and morespontaneous communication. Non-verbal or minimally verbal children may show increased use of alternativecommunication systems and greater engagement with their environment. These gains reflect improved functionalconnectivity between the temporal, frontal, and limbic regions involved in social processing.
Attention, Focus, and Impulse Regulation
In children with ADHD, and in the ADHD presentations that co-occur with ASD, families and educators haveobserved improvements in the ability to sustain attention on tasks, reduced impulsivity in social and academicsettings, and improved working memory. These gains are consistent with improved prefrontal-subcortical circuitfunction. Cytotron is used as a complementary modality and does not replace existing pharmacological orbehavioural management.
Sensory Processing and Emotional Regulation
Sensory hypersensitivity — to sound, light, texture, or touch — is a significant source of distress in ASD andcontributes to emotional dysregulation and meltdown behaviours. TMP normalisation and improved GABAergictone may contribute to a calmer sensory baseline, reduced sensory-triggered distress, and improved emotionalself-regulation over the course of treatment and follow-up.
Developmental Milestone Acquisition
In younger children with ASD and co-occurring developmental delay, families have reported acceleration indevelopmental milestone acquisition — including play skills, motor imitation, self-care, and early academicreadiness. These gains are most pronounced when Cytotron is combined with structured therapeutic intervention(ABA, speech, occupational therapy) during and after the treatment cycle. For developmental gains of this nature,the full picture typically emerges after three cycles: early cycles may produce subtle shifts in engagement andresponsiveness, with more pronounced functional gains consolidating through the second and third cycles.Individual response varies and cannot be predicted in advance.
Neural Connectivity
BDNF-driven synaptic strengthening and long-rangecircuit support
Synaptic Plasticity
CREB-mediated pathway for new circuit formation
Cortical Regulation
TMP normalisation reducing sensoryhyperexcitability
Attention & Focus
Prefrontal dopaminergic circuit support for ADHD

Everything You Need
to Know—Upfront

We help patients and healthcare partners navigate personalized care and innovative medtech solutions—here’s what most people ask before getting started with us
Can Cytotron therapy help children with Autism?

Cytotron RFQMR-FRB therapy aims to support neural connectivity and synaptic function in children withAutism Spectrum Disorder. By activating BDNF, CREB-mediated plasticity, and TMP normalisationpathways, the therapy targets the underlying biophysical environment of the autistic brain. Improvement isfunctional and gradual — not a cure — but families have reported gains in social engagement,communication, eye contact, and sensory tolerance.

Can Cytotron therapy help children with ADHD?

In ADHD, RFQMR-FRB therapy targets the prefrontal cortical circuits involved in attention regulation,working memory, and impulse control. By modulating transmembrane potential and supportingdopaminergic and noradrenergic signalling pathways, therapy may improve sustained attention, reduceimpulsivity, and support executive function. Cytotron is used as a complementary modality alongsideexisting behavioural and pharmacological management.

Is Cytotron treatment safe for children with ASD or ADHD?

Cytotron RFQMR-FRB therapy is non-surgical, painless, and does not involve radiation, injections, oranaesthesia. Each session lasts approximately 60 minutes and a parent or carer may remain presentthroughout. There are no known side effects at prescribed clinical dosimetry. Before treatment is confirmed,every child undergoes a structured clinical assessment by Ardram’s medical team covering medical history,neuroimaging, implants and devices, active conditions, and current therapies. This assessment screens forcontraindications and ensures the treatment plan is appropriate for the individual child. Eligibility is notassumed — it is determined.

Can Cytotron be used alongside ABA, speech therapy, occupational therapy, ormedication?

Yes. Cytotron is routinely integrated with Applied Behaviour Analysis (ABA), speech and language therapy,occupational therapy, and pharmacological management including stimulant medication for ADHD. It doesnot require any existing treatment to be discontinued or modified. The regenerative effects of RFQMR-FRBmay enhance the brain’s responsiveness to concurrent behavioural and educational interventions.

My child has both Autism and ADHD. Can Cytotron address both?

Yes. The biophysical mechanisms targeted by RFQMR-FRB therapy — BDNF upregulation, CREBmediated synaptic plasticity, TMP normalisation, and dopaminergic circuit support — are relevant to bothconditions simultaneously. A significant proportion of children with ASD also meet criteria for ADHD. Thepersonalised dosimetry plan is designed to target the specific brain regions and connectivity patternsidentified in the individual child’s MRI and clinical profile

What age range is suitable for treatment?

Eligibility is assessed individually through Ardram’s structured clinical assessment process, which coversthe child’s neuroimaging, developmental and medical history, current therapies, and a systematic review ofcontraindications. There is no single fixed lower age limit; suitability is determined by the clinical team foreach individual. Contact us to discuss your child’s specific situation and we will advise on next steps.